Private medical labs in France could face cuts in government reimbursement, slashing their operating profit. https://t.co/yGQ9mcBEeg ...

Photo courtesy of Labcorp (PRNewsfoto/Labcorp) Photo courtesy of Labcorp (PRNewsfoto/Labcorp) Laboratory testing plays a critical role in healthcare, informing nearly 70% of clinical decisions and often serving as the first step in diagnosing and managing patient conditions. Yet research shows providers spend more than three hours a day on responsibilities including documentation and test ordering—time that could be spent with patients. According to a recent American Medical Association (AMA) survey, 57% of ...

PGDx elio tissue complete makes it easier for laboratories to bring testing in-house while lowering costs, accelerating implementation, and helping patients get tested sooner. First-and-only test of its kind approved under new European Union regulations expands access to personalized cancer care for patients across the EU BURLINGTON, N.C., July 29, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today PGDx elio™ tissue complete has been ...

Financial Performance - Q2 2025 - Total Adjusted EBITDA for Q2 2025 was $627.8 million[6], compared to $574.6 million in Q2 2024[6], an increase - The company's Q2 2025 revenue, as reported, reached $3.5273 billion[21], a 9.5% increase year-over-year from $3.2209 billion in Q2 2024[21] - Adjusted earnings per share for Q2 2025 was $4.35[23], compared to $3.94 in Q2 2024[23] Revenue Breakdown and Growth - Enterprise revenue, as reported, for Q2 2025 was $3.527 billion[8], reflecting a 9.5% year-over-year growth[8] - Diagnostics Laboratories revenue, as reported, for Q2 2025 was $2.749 billion[8], showing an 8.9% year-over-year growth[8] - Biopharma Laboratory Services revenue, as reported, for Q2 2025 was $785 million[8], a significant 11% increase year-over-year[8] Outlook for 2025 - The company projects full-year 2025 revenue for Labcorp Enterprise to be between $13.98 billion and $14.13 billion[18], representing a 7.5% to 8.6% increase versus 2024 results[18] - The company anticipates adjusted EPS for 2025 to be in the range of $16.05 to $16.50[18], a 10.1% to 13.2% increase compared to 2024[18] Biopharma Laboratory Services Metrics - The Trailing Twelve Month (TTM) Net Orders ending June 30, 2025, for Biopharma Laboratory Services reached $3.34 billion[17], with a Net Book-to-Bill ratio of 1.11x[17] - As of June 30, 2025, the backlog for Biopharma Laboratory Services was $8.71 billion[17], with an estimated $2.71 billion expected to convert to revenue in the next twelve months[17]

Core Viewpoint - Labcorp Holdings (LH) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook based on rising earnings estimates, which significantly influence stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system emphasizes the importance of earnings estimate revisions, which are strongly correlated with near-term stock price movements [4][6]. - Institutional investors utilize earnings estimates to determine the fair value of stocks, leading to buying or selling actions that affect stock prices [4]. Labcorp's Earnings Outlook - For the fiscal year ending December 2025, Labcorp is expected to earn $16.05 per share, with a 0.3% increase in the Zacks Consensus Estimate over the past three months [8]. - The upgrade reflects an improvement in Labcorp's underlying business, which is likely to drive the stock price higher as investors respond positively to this trend [5][10]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have averaged a +25% annual return since 1988 [7]. - Labcorp's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting a strong potential for market-beating returns in the near term [9][10].

Core Viewpoint - Quest Diagnostics (DGX) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system reflects changes in earnings estimates, which are strongly correlated with near-term stock price movements, particularly due to institutional investors' reliance on these estimates for valuation [4][6]. - An increase in earnings estimates typically leads to higher fair value calculations for stocks, prompting institutional investors to buy or sell, thus affecting stock prices [4]. Company Performance and Outlook - The upgrade for Quest Diagnostics signifies an improvement in its underlying business, which is expected to drive the stock price higher as investors respond positively to this trend [5][10]. - Analysts project that Quest Diagnostics will earn $9.70 per share for the fiscal year ending December 2025, with a slight increase of 0.1% in the Zacks Consensus Estimate over the past three months [8]. Zacks Rank System - The Zacks Rank system categorizes stocks based on earnings estimate revisions, with only the top 20% of stocks receiving a "Strong Buy" or "Buy" rating, indicating superior potential for market-beating returns [9][10]. - The Zacks Rank 2 for Quest Diagnostics places it among the top 20% of stocks covered by Zacks, suggesting a favorable outlook for the stock in the near term [10].

Financial Results Announcement - Labcorp Holdings Inc. will release its financial results for the second quarter of 2025 before the market opens on July 24, 2025 [1] - A conference call and webcast will be held at 9 a.m. ET on the same day to discuss the results [1] Webcast Details - The call will be available via live webcast on the Labcorp Investor Relations website, with registration required for dial-in access [2] - Participants are encouraged to join 10 minutes early, but can register and join at any time during the call [2] Replay Information - A replay of the webcast will be accessible approximately two hours after the live event and will remain available until July 11, 2026 [3] Company Overview - Labcorp is a global leader in laboratory services, aiding healthcare professionals and researchers in decision-making [4] - The company employs nearly 70,000 individuals and operates in approximately 100 countries, supporting over 75% of new drugs approved by the FDA in 2024 [4] - Labcorp conducts more than 700 million tests annually for patients worldwide [4]

Core Viewpoint - Labcorp is expanding its offerings to include FDA-approved self-collection solutions for HPV and STI testing, aiming to improve access to cervical cancer screenings and sexually transmitted infection tests [1][4][5] Group 1: Cervical Cancer Screening - Each year, over 13,000 women in the U.S. are diagnosed with cervical cancer, with approximately 4,000 deaths from this preventable disease [3] - HPV testing is essential for early intervention and treatment, yet one in four women of screening age were not up to date with cervical cancer screening recommendations in 2021 [3] - The FDA approved self-collection tests for cervical cancer screenings in 2024, providing a less invasive alternative to traditional Pap smears [4][5] Group 2: STI Testing - Labcorp will offer a vaginal swab self-collect option for STI testing, including chlamydia, gonorrhea, trichomonas, and mycoplasma genitalium [5] - In 2023, the CDC reported 2.4 million cases of STIs diagnosed and reported, highlighting the need for early detection to minimize long-term effects [5] - Self-collection for STI testing can empower individuals to take control of their sexual health and expedite the diagnosis-to-treatment timeline [6] Group 3: Accessibility and Convenience - The self-collection options will be available starting April 7, allowing patients to complete tests privately in healthcare settings or at Labcorp's 2,200 Patient Service Centers nationwide [7][9] - Results from the tests will be sent electronically to both the ordering physician and the patient via their Labcorp Patient account [9]